Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

Pfizer said on Wednesday its experimental pneumococcal vaccine showed significantly stronger immune response than its current shot, including up ​to 15-fold higher antibody levels against a key strain, ‌in a mid-stage study.

Reuters • 10 hours ago

How S&P Drug Titan Pfizer Plans To Outdo Its Own $6 Billion Franchise

The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study.

Investors Business Daily • 10 hours ago

Pfizer Builds Oncology Growth Around Padcev and Pipeline Expansion

PFE bets on Padcev, biosimilars and late-stage pipeline candidates to drive long-term oncology growth amid pressure on legacy drugs.

Zacks Investment Research • 3 hours ago

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced data from its Phase 2 study (NCT06524414) evaluating the safety, tolerability and immunogenicity of a four-dose series of its investigational 25-valent pneumococcal conjugate vaccine candidate PF-07872412 (25vPnC) in infants compared to four doses of PREVNAR 20 at months 2, 4, 6 and 12-15. Based on the strong immune responses observed for all 25vPnC serotypes from Phase 2, compared to PREVNAR 20, Pfizer is confident that the req.

Business Wire • 10 hours ago

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, today announced a strategic collaboration with Pfizer Inc. to advance the development of Pfizer's oncology portfolio through a science‑driven and scaled research program designed to bring promising therapies to patients faster and closer to home. Central to the collaboration is SCRI's Accelero™, a next-generation clinic.

Business Wire • 6 hours ago

FQ1 Healthcare Dividend Roundup: Johnson & Johnson Keeps Outshining Pfizer

Johnson & Johnson offers a superior return/risk profile versus Pfizer, driven by consistency and operational stability. PFE's far lower valuation (FWD P/E 8.55x, PEGY 0.97x) and far higher yield (6.79%) are certainly attractive. But JNJ's 63-year streak of dividend growth, lower payout ratio (48.46%), ongoing buybacks, and stable inventory all point to far superior consistency.

Seeking Alpha • 2 hours ago

The SoFi CEO Just Bought 70,000 Shares With His Own Money. Here Are Four More Under $30 Worth a Closer Look

With markets at elevated multiples in May 2026, low share prices can mislead investors into thinking quality is out of reach.

24/7 Wall Street • May 19, 2026

Rate Cuts Are Off the Table. Here Are 2 Stocks Under $30 Built Exactly for This Moment

With short-term rates still elevated, tariff uncertainty churning through earnings models, and credit spreads widening at the margins, balance sheet quality has quietly become the most underrated factor in equity selection.

24/7 Wall Street • May 19, 2026

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

10 abstracts, including two oral presentations, reinforce Astellas' long-term commitment to advancing oncology care TOKYO, May 18, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced it will present new data across its oncology portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29 - June 2 in Chicago, reinforcing Astellas' sustained commitment to improving outcomes for people living with cancer. The data will provide further insight into the durable efficacy of established treatment approaches, their use in clinical practice, and ongoing areas of research and development.

PRNewsWire • May 18, 2026

3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now

Shares of Pfizer, Novo Nordisk, and PDD Holdings trade at incredibly low valuations right now. These stocks are trading at significant discounts relative to their future earnings.

The Motley Fool • May 18, 2026